Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Insights, 2023 Updates | Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Insights, 2023 Updates | Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies
As per DelveInsight’s assessment, globally, about 120+ key pharma and biotech companies are working on 460+ pipeline drugs in the Chimeric Antigen Receptor (CAR) T-Cell Therapy landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Insight, 2023″ report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  CAR T-cell Therapy Market. 

The CAR T-cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Analysis

Chimeric Antigen Receptor (CAR) T-Cell Therapy Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging CAR T-cell Therapy in the Market and the aggregate therapies developed by major pharma companies.

  • It accesses the different CAR T-cell Therapy therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the CAR T-cell Therapy Market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates


Route of Administration

CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Intravenous

  • Intramuscular

  • Subcutaneous

  • Intratumoral


Mechanism of Action

Products have been categorized under various Mechanisms of Action, such as

  • T lymphocyte replacements

  • Immunologic cytotoxicity


Learn How the Ongoing Clinical & Commercial Activities will Affect the CAR T-cell Therapy Therapeutic Segment @

Chimeric Antigen Receptor (CAR) T-Cell TherapyTherapeutics Landscape

There are approx. 120+ key companies which are developing Chimeric Antigen Receptor (CAR) T-Cell Therapy. Currently, JW Therapeutics is leading the therapeutics market with its CAR-T drug candidates in the most advanced stage of clinical development.

The Leading Players in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Include:

AbbVie, AbCLon, Actinium Pharmaceuticals, Adagene, Adicet Bio, AffyImmune Therapeutics, AgenTus Therapeutics, Allife Medical Science and Technology, Allogene Therapeutics, Amgen/Kite Pharma, Anixa Biosciences, Apceth Biopharma, Arbele Limited, Arcellx Inc, Atara Biotherapeutics, Atossa Therapeutics, Atreca/Xenor, Aurora Biopharma, Autolus Limited, Beam Therapeutics, Beijing Biohealthcare Biotechnology, Beijing Biohealthcare Biotechnology, Beijing Doing Biomedical, Beijing Immunochina Medical Science and Technology, Beijing Mario Biotech, Bellicum Pharmaceuticals, Benitec Biopharma Limited, Bioatla, Bioceltech Therapeutics, BioNTech, Biosceptre, Bluebird Bio, BrightPath Therapeutics, Bristol-Myers Squibb, Caribou Biosciences, Carina Biotech, CARsgen, Carsgen Therapeutics, Cartesian Therapeutics, Cartherics, CASI Pharmaceuticals/Juventas Cell Therapy, Celgene, Cellectis, Cellular Biomedicine Group, Celyad Oncology SA, Chimeric Therapeutics, Chongqing Precision Biotechnology Co., Ltd., Cogent Biosciences, Creative Biolabs, CRISPR Therapeutics, Curocell, Elpis Biopharmaceuticals, Endocyte, Enlivex Therapeutics Ltd, Eureka Therapeutics, Eutilex/Utilities, Exuma, FastBack Bio, Fate Therapeutics, Formula Pharmaceuticals, Fujifilm Holdings Corporation, Fundamenta Therapeutics, GC Cell, Genus oncology, Gilead Sciences, GlaxoSmithKline, Glycotype, Gracell Biotechnology, Grand Vista Biotechnology, Guangdong Zhaotai InVivo Biomedicine Co. Ltd., Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology Inc., Ltd., Helix BioPharma, Helocyte, Hemalogix, Henan Hualong Biotechnology, HRAIN Biotechnology, Humorigin, Hunan Zhaotai Yongren Medical Innovation, iCarTAB BioMed, iCell Gene Therapeutics, Immune Therapeutics, Immuneel, Immunicum, IN8Bio, InnoBation, Innovative Cellular Therapeutics, Innovent Biologics, Intellia Therapeutics, Janssen Pharmaceuticals, JW Therapeutics, KAEDI, Kecellitics Biotech Company Ltd, Kiromic BioPharma, Kite Pharma, Kuur Therapeutics, Liminatus Pharma, Luminary Therapeutics, Maxcyte, Medisix Therapeutics, Miltenyi Biotec, Minerva Biotechnologies, MolMed, Mustang Bio, Nanjing KAEDI Biotech, Noile-Immune Biotech, Novartis Pharmaceuticals, Obsidian Therapeutics, Oncternal Therapeutics, Orgenesis, Oxford Biomedica, Pepromene bio, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Poseida Therapeutics, Precigen, Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Protheragen, PTX Therapeutics, REGENERON, Sana Biotechnology, Sangamo, Senlang Bio, Sensei Biotherapeutics, Servier, Shanghai Biomed-union Biotechnology, Shanghai GeneChem Co., Ltd., Shanghai Longyao Biotechnology, Shanghai Unicar-Therapy Bio-medicine Technology, Shenzhen BinDeBio, Sinobioway Cell Therapy Co., Ltd., Sorrento Therapeutics, SymVivo, Synthekine, Takeda / Noile-Immune Biotech, Targazyme, TC BioPharm, Tessa Therapeutics Ltd., The Beijing Pregene Science and Technology Company, Tianjin Mycure Medical Technology, TILT Biotherapeutics, Timmune Biotech, Tmunity Therapeutics, ToolGen, TrakCel, Transgene, UWELL Biopharma, VCANBIO Cell & Gene Engineering Corporation, Ltd, VorBio, Wellington Zhaotai Therapies, WindMIL Therapeutics, Wugen, Wuhan Bio-Raid Biotechnology, Wuhan Sian Medical Technology, Xi’An Yufan Biotechnology, Xyphos Biosciences, Yake Biotechnology, Ziopharm Oncology Inc. Intrexon, and many others.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Emerging and Marketed Drugs Covered in the Report Include:

  • CD19-targeted CAR-T cells: Sinobioway Cell Therapy

  • CEA CAR T: Sorrento Therapeutics

  • CT 103A: Innovent Biologics

  • CTL119: Novartis

  • Descartes-11: Cartesian Therapeutics

  • EPCAM-targeted CAR T-cells: Sinobioway Cell Therapy

  • JWCAR029: JW Therapeutics

  • MB-CART2019.1: Miltenyi Biomedicine

  • TT11: Tessa Therapeutics

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. CAR T-cell Therapy Current Treatment Patterns

4. CAR T-cell Therapy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. CAR T-cell Therapy Late Stage Products (Phase-III)

7. CAR T-cell Therapy Mid-Stage Products (Phase-II)

8. CAR T-cell Therapy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. CAR T-cell Therapy Discontinued Products

13. CAR T-cell Therapy Product Profiles

14. Key Companies in the CAR T-cell Therapy Market

15. Key Products in the CAR T-cell Therapy Therapeutics Segment

16. Dormant and Discontinued Products

17. CAR T-cell Therapy Unmet Needs

18. CAR T-cell Therapy Future Perspectives

19. CAR T-cell Therapy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States